Jon Macicior

Dr. Jon Macicior

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JMJon Macicior
Jon Macicior
BMBeatriz Marcos-Ramiro
Beatriz Marcos-Ramiro
Silvia Ortega-GutiérrezSilvia Ortega-Gutiérrez
Silvia Ortega-Gutiérrez
Hutchinson–Gilford progeria syndrome (HGPS), or progeria, is an extremely rare disorder that belongs to the class of laminopathies, diseases characterized by alterations in the genes that encode for the lamin proteins or for their associated interacting proteins. In particular, progeria is caused by a point mutation in the gene that codifies for the lamin A gene. This mutation ultimately leads to the biosynthesis of a mutated version of lamin A called progerin, which accumulates abnormally in the nuclear lamina. This accumulation elicits several alterations at the nuclear, cellular, and tissue levels that are phenotypically reflected in a systemic disorder with important alterations, mainly in the cardiovascular system, bones, skin, and overall growth, which results in premature death at an average age of 14.5 years. In 2020, lonafarnib became the first (and only) FDA approved drug for treating progeria. In this context, the present review focuses on the different therapeutic strategies currently under development, with special attention to the new small molecules described in recent years, which may represent the upcoming first-in-class drugs with new mechanisms of action endowed with effectiveness not only to treat but also to cure progeria.

23 December 2020 in European Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
NKNora Khiar‐Fernández
Nora Khiar‐Fernández
JMJon Macicior
Jon Macicior
BMBeatriz Marcos‐Ramiro
Beatriz Marcos‐Ramiro
Silvia Ortega-GutiérrezSilvia Ortega-Gutiérrez
Silvia Ortega-Gutiérrez

22 October 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
JMJon Macicior
Jon Macicior
MTMARCELINO TELECHEA
MARCELINO TELECHEA
DFDaniel Fernández
Daniel Fernández
AGAlba García-Martín
Alba García-Martín
ÁCÁngeles Canales
Ángeles Canales
Silvia Ortega-GutiérrezSilvia Ortega-Gutiérrez
Silvia Ortega-Gutiérrez
Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder caused by a mutation in the LMNA gene, leading to the production of progerin, an aberrant and toxic form of lamin A. Due to its hydrophobic nature, progerin accumulates at the nuclear membrane, disrupting nuclear architecture, impairing cellular functions, and ultimately resulting in death around adolescence. Reducing progerin levels is considered the most effective strategy to improve disease progression. To date, small-molecule approaches have primarily targeted progerin upstream mechanisms to indirectly reduce its levels. In this study, we report the development of first-generation proteolysis targeting chimeras (PROTACs) designed to directly degrade progerin, establishing a novel therapeutic paradigm for HGPS. We identify UCM-18142 (compound 2) as the first PROTAC capable of selectively degrading progerin. Treatment with UCM-18142 results in significant improvements in cellular phenotype in both HGPS patient-derived cells and a murine model, including enhanced proliferation, reduced senescence markers, and normalization of nuclear and mitochondrial abnormalities. Additionally, transcriptomic analysis of treated human cells reveals the cellular pathways modulated by compound. Remarkably, PROTAC 2 reduces progerin levels in vivo, supporting the therapeutic potential of this direct-targeting approach and opening new avenues for intervention in HGPS and related laminopathies.